Identification of CDKL3 as a critical regulator in development of glioma through regulating RRM2 and the JNK signaling pathway

Yong Cui,Zhigang Yang,Hongxiang Wang,Yong Yan,Qilin Huang,Zhenyu Gong,Fan Hong,Xu Zhang,Weiqing Li,Juxiang Chen,Tao Xu
DOI: https://doi.org/10.1111/cas.15010
IF: 5.7
2021-06-28
Cancer Science
Abstract:<p>Glioma is one of the most commonly diagnosed intracranial malignancies. The molecular mechanism underlying the development of glioma is still largely unknown. In this study, we present the first report concerning the function and mechanism of CDKL3 in the development and prognosis of glioma. It is demonstrated that CDKL3 was up-regulated in glioma tissues and could independently predict poor prognosis of patients. Silencing CDKL3 in glioma cells could inhibit cell proliferation and migration, induce cell apoptosis and cell cycle arrest, while the over-expression of CDKL3 promoted cell proliferation. The <i>in vivo</i> experiments also indicated that knockdown of CDKL3 significantly suppressed tumor growth of glioma. Gene expression profiling of CDKL3 knockdown U87 cells identified RRM2 as a potential target of CDKL3, which was proved to have direct interaction with CDKL3. Given similar effects on glioma development with CDKL3, knockdown of RRM2 could rescue the effects of CDKL3 over-expression on glioma cells. Moreover, knockdown of CDKL3 or RRM2 suppressed the activity of JNK signaling while CDKL3 over-expression exhibited contrary effects. In conclusion, our results identified CDKL3 as a promotor for glioma, probably through the regulation of RRM2 and activation of JNK signalling pathway, highlighting the significance of CDKL3 as a promising therapeutic target of glioma.</p>
oncology
What problem does this paper attempt to address?